Nationwide Hypophosphatemic Rickets Cohort Study
Hypophosphatemic rickets (HR) is a rare renal phosphate wasting disorder commonly related to X-linked form, caused by PHEX mutations and its treatment and follow-up is challenging due to imperfect treatment options. Here we presented nationwide data on HR with initial and follow-up data on the patients. From 24 centers, 166 patients were included in the study data. Genetic analysis (n:75) showed PHEX mutation in 80% patients. The mean follow-up period of the patients was 6.7± 2.4 years. During first 3 year treatment (n:91), mild increase in phosphate , decrease in ALP and, elevation in PTH levels had been detected. The height SDS were -2.38, -2.77, -2.72, -2.47 at intitial, 1st, 2nd and 3rd year of treatment, respectively (p>0.05). In follow-up: 36% of the patients showed complete or significant improvement in leg deformities, and, these patients had similar phosphate levels at presentation with better levels in 1st and 2nd years of treatment, even the treatment doses of phosphate were similar. Furthermore, 27 patients developed nephrocalcinosis, the patients showed no difference in biochemical differences in presentation and follow-up, but 3rd year PTH was higher, however, higher treatment dose of phosphate and calcitriol has been detected in nephrocalcinosis group. HR treatment and follow-up is challenging and our results showed higher treatment doses leading nephrocalcinosis without any change in serum levels, suggesting given higher doses lead higher phoshaturia probably through the stimulation FGF23. However, higher calcitriol doses could improve bone deformities. Safer and more efficacious therapies are needed.